Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer.
Guerin M, Gonçalves A, Toiron Y, Baudelet E, Pophillat M, Granjeaud S, Fourquet P, Jacot W, Tarpin C, Sabatier R, Agavnian E, Finetti P, Adelaide J, Birnbaum D, Ginestier C, Charafe-Jauffret E, Viens P, Bertucci F, Borg JP, Camoin L.
Guerin M, et al. Among authors: toiron y.
Oncotarget. 2018 Sep 18;9(73):33762-33777. doi: 10.18632/oncotarget.26031. eCollection 2018 Sep 18.
Oncotarget. 2018.
PMID: 30333908
Free PMC article.